IGM Biosciences Financial Statements (IGMS)
|
|
|
|
Report date
|
|
|
26.03.2020 |
30.03.2021 |
29.03.2022 |
30.03.2023 |
07.03.2024 |
|
08.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
1.07 |
2.13 |
|
2.92 |
|
Operating Income, bln rub |
|
|
-44.5 |
-83.3 |
-165.3 |
-228.0 |
-263.5 |
|
-234.7 |
|
EBITDA, bln rub |
? |
|
-40.8 |
-77.8 |
-157.4 |
-221.9 |
-253.4 |
|
-226.3 |
|
Net profit, bln rub |
? |
|
-42.5 |
-80.3 |
-160.7 |
-214.2 |
-246.4 |
|
-219.8 |
|
|
OCF, bln rub |
? |
|
-45.1 |
-67.3 |
-124.3 |
-5.85 |
-192.2 |
|
-166.2 |
|
CAPEX, bln rub |
? |
|
2.34 |
17.5 |
13.2 |
10.2 |
12.4 |
|
6.44 |
|
FCF, bln rub |
? |
|
-47.5 |
-84.8 |
-137.6 |
-16.1 |
-204.6 |
|
-172.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
44.5 |
83.3 |
165.3 |
229.0 |
265.6 |
|
233.2 |
|
Cost of production, bln rub |
|
|
2.33 |
3.58 |
7.72 |
10.6 |
213.8 |
|
6.63 |
|
R&D, bln rub |
|
|
35.3 |
65.0 |
127.0 |
179.3 |
215.5 |
|
181.7 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
3.98 |
|
|
Assets, bln rub |
|
|
261.4 |
408.6 |
298.1 |
513.5 |
423.4 |
|
304.5 |
|
Net Assets, bln rub |
? |
|
-107.2 |
-188.6 |
-353.7 |
-574.8 |
203.2 |
|
78.9 |
|
Debt, bln rub |
|
|
14.7 |
12.2 |
28.8 |
41.2 |
40.5 |
|
45.9 |
|
Cash, bln rub |
|
|
236.6 |
366.3 |
229.5 |
427.2 |
337.7 |
|
218.8 |
|
Net debt, bln rub |
|
|
-221.9 |
-354.0 |
-200.8 |
-386.0 |
-297.2 |
|
-172.9 |
|
|
Ordinary share price, rub |
|
|
38.2 |
88.3 |
29.3 |
17.0 |
8.31 |
|
4.74 |
|
Number of ordinary shares, mln |
|
|
9.00 |
30.7 |
33.5 |
41.5 |
52.3 |
|
60.7 |
|
|
Market cap, bln rub |
|
|
343 |
2 715 |
982 |
707 |
435 |
|
288 |
|
EV, bln rub |
? |
|
121 |
2 361 |
781 |
321 |
138 |
|
115 |
|
Book value, bln rub |
|
|
-107 |
-189 |
-354 |
-575 |
203 |
|
79 |
|
|
EPS, rub |
? |
|
-4.73 |
-2.61 |
-4.80 |
-5.16 |
-4.71 |
|
-3.62 |
|
FCF/share, rub |
|
|
-5.28 |
-2.76 |
-4.11 |
-0.39 |
-3.91 |
|
-2.85 |
|
BV/share, rub |
|
|
-11.9 |
-6.13 |
-10.6 |
-13.8 |
3.89 |
|
1.30 |
|
|
EBITDA margin, % |
? |
|
|
|
|
-20 756% |
-11 895% |
|
-7 755% |
|
Net margin, % |
? |
|
|
|
|
-20 042% |
-11 569% |
|
-7 534% |
|
FCF yield, % |
? |
|
-13.8% |
-3.12% |
-14.0% |
-2.27% |
-47.1% |
|
-60.0% |
|
ROE, % |
? |
|
39.7% |
42.6% |
45.4% |
37.3% |
-121.2% |
|
-278.5% |
|
ROA, % |
? |
|
-16.3% |
-19.7% |
-53.9% |
-41.7% |
-58.2% |
|
-72.2% |
|
|
P/E |
? |
|
-8.07 |
-33.8 |
-6.11 |
-3.30 |
-1.76 |
|
-1.31 |
|
P/FCF |
|
|
-7.23 |
-32.0 |
-7.14 |
-44.0 |
-2.12 |
|
-1.67 |
|
P/S |
? |
|
|
|
|
661.1 |
204.1 |
|
98.5 |
|
P/BV |
? |
|
-3.20 |
-14.4 |
-2.78 |
-1.23 |
2.14 |
|
3.64 |
|
EV/EBITDA |
? |
|
-2.98 |
-30.4 |
-4.96 |
-1.45 |
-0.54 |
|
-0.51 |
|
Debt/EBITDA |
|
|
5.44 |
4.55 |
1.28 |
1.74 |
1.17 |
|
0.76 |
|
|
R&D/CAPEX, % |
|
|
1 509% |
371.6% |
959.1% |
1 757% |
1 741% |
|
2 822% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
954.7% |
581.3% |
|
220.6% |
|
| IGM Biosciences shareholders |
